SME Times is powered by   
Search News
Just in:   • Rs 11,200 crore Noida International Airport gives major connectivity boost, drives economic growth  • Crude oil drops over 5 pc this week, hovers above $100 amid global uncertainty  • More Indian ships to sail through Strait of Hormuz: Govt  • All fuel outlets operating normally, rapid rollout of PNG connections underway: Centre  • Lighting the Future: How Veltrox Industries is Powering the Shift to Smart, Customized LED Solutions 
Last updated: 15 Nov, 2018  

Tablet.9.Thmb.jpg Pharma exports rising post GST implementation: Minister

Tablet.9.jpg
   Top Stories
» Rs 11,200 crore Noida International Airport gives major connectivity boost, drives economic growth
» Crude oil drops over 5 pc this week, hovers above $100 amid global uncertainty
» All fuel outlets operating normally, rapid rollout of PNG connections underway: Centre
» Sensex, Nifty climb one pc amid ceasefire hopes; oil price drops 7 pc
» Gold, silver plunge up to 6 pc on global weakness, rupee hits 93.84 against US dollar
SME Times News Bureau | 15 Nov, 2018

Exports from the Indian pharmaceutical sector may reach Rs 3,27,700 crores during the current fiscal due to positive impacts of implementation of Goods and Services Tax (GST), said Minister of State for Chemicals & Fertilizers Mansukh Mandaviya on Thursday.

As per estimates, the export figure for the current year is likely to be Rs 3,27,700 crore, which will be almost 12% higher than the export figure of Pre-GST regime (2016-17), said Mandaviya in an official statement in New Delhi.

Exports from pharma sector during 2016-17 were Rs 2,75,852 crore while post-GST, in the year 2017-18, they were recorded at Rs 3,03,526 crore, which is 10% higher than the Pre-GST Regime, he added.

He added that before GST, annual turnover of the sector (as on 31.05.2017) was Rs 1,14,231 crores while after GST, the annual turnover of Pharma sector (as on 31.05.2018) touched Rs 1,31,312 crores, which is 6% higher than the Pre-GST regime.

Impact of Goods and Services Tax (GST) on Pharma sector has largely been positive and constructive, the minister pointed out.

Further, he informed that there has been a significant jump in number of drug approvals from 7,857 before GST (01.07.2016 to 30.06.2017) to 10,446 post-GST (01.07.2017 to 30.06.2018).

Elaborating on the reasons for this positive impact post-GST, Mandaviya said that under the ‘One Nation, One Tax’ regime, the removal of complexity of multiple taxes has reduced their cascading effect on the final product.

GST is expected to decrease the manufacturing cost in view of merging of different taxes levied earlier and promote ease of doing business. It will create one single market for all stakeholders with equal chance towards development, he said.

Mandaviya informed that due to discontinuation of Central Sales Tax post-GST, it will reduce transaction costs, as inter-state transaction between two dealers will become tax neutral.

Now, the pharma companies can consolidate their warehouses at strategic locations, effecting a reduction in cost of distribution. As a result, it will benefit warehouse strategy and improve supply chain efficiency in pharma sector, the minister explained.

 
Print the Page
Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
₹91.35
89.65
UK Pound
₹125.3
₹121.3
Euro
₹108.5
₹104.85
Japanese Yen ₹58.65 ₹56.8
As on 19 Feb, 2026
  Daily Poll
What is the biggest war impact on MSMEs?
 Export Disruption
 Raw Material Spike
 Freight Cost Surge
 Payment Delays
 Currency Volatility
 All
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter